<DOC>
	<DOCNO>NCT02216214</DOCNO>
	<brief_summary>The purpose study ass efficacy , safety tolerability mirabegron versus placebo treatment old adult subject OAB .</brief_summary>
	<brief_title>Study Evaluate Efficacy , Safety , Tolerability Mirabegron Older Adult Subjects With Overactive Bladder ( OAB )</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Mirabegron</mesh_term>
	<criteria>Inclusion Criteria assess Visit 1 ( Screening ) : Subject willing able complete micturition diary questionnaire correctly . Subject symptom wet overactive bladder ( OAB ) ( urinary frequency urgency incontinence ) great equal 3 month prior Screening . Subject agree participate another interventional study time screen final study visit . Inclusion Criteria assess placebo runin period Visit 3 ( Baseline ) : Subject continue meet inclusion criterion Visit 1 . Subjects must experience least one incontinence episode placebo runin period base 3day micturition diary . Subject must experience least 3 episode urgency ( grade 3 4 ) base 3day micturition diary . Subject must experience average great equal 8 micturitions/day base 3day micturition diary . Exclusion Criteria assess Visit 1 ( Screening ) : Subject ongoing symptom suggestive bladder outlet obstruction ( BOO ) history BOO currently well control . Subject PostVoid Residual Volume ( PVR ) great 150 mL . Subject neurogenic bladder neurological dysfunction injury could affect low urinary tract nerve supply . Subject significant stress incontinence mixed stress/urgency incontinence stress predominant factor determine Investigator ( female subject confirm cough provocation test ) . Subjects history stress incontinence currently treat ( e.g . remote history surgery stress incontinence ) may include long pas cough provocation test . Subject indwell catheter practice intermittent selfcatheterization . Subject evidence Urinary Tract Infection ( UTI ) . Urine culture sensitivity perform positive leukocyte , nitrite , turbidity , investigator 's discretion confirm culture great 100,000 cfu/mL . If subject UTI Screening ( Visit 1 ) , subject rescreened successful treatment UTI ( confirm laboratory result negative urine culture ) . Subject chronic inflammatory condition interstitial cystitis , bladder stone , previous pelvic radiation therapy , previous current malignant disease pelvic organ ( i.e. , within confines pelvis include bladder rectum sex uterus , ovary , fallopian tube female ; organ lower gastrointestinal tract necessarily consider pelvic organ distal ascend colon , full transverse colon proximal portion descend colon abdomen ) . Subject resides nursing home . Subject likely enter hospital nursing home due medical instability within next 6 month opinion Investigator . Subject receive intravesical injection past 12 month botulinum toxin , resiniferatoxin , capsaicin . Subject received electrostimulation therapy OAB ( e.g . sacral nerve stimulation Percutaneous Tibial Nerve Stimulation [ PTNS ] ) . Subject begin changed bladder training program pelvic floor exercise less 30 day prior Screening . Subject moderate severe hepatic impairment define ChildPugh Class B C. Subject severe renal impairment define estimate creatinine clearance le 29 mL/min determine Estimated Glomerular Filtration Rate ( eGFR , CockroftGault , MDRD formula ) . A subject end stage renal disease undergoing dialysis also candidate study . Subject severe uncontrolled hypertension , define sit systolic blood pressure great equal 180 mmHg and/or diastolic blood pressure great equal 110 mmHg . Subject evidence QT prolongation electrocardiogram ( ECG ) define QTc great 450 msec male , QTc great 470 msec female know history QT prolongation . Subject clinically significant ECG abnormality , determine Investigator . Subject aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) great 2x upper limit normal ( ULN ) , γGT great 3x ULN consider clinically significant Investigator . Subject hypersensitivity component mirabegron , βAR agonist , inactive ingredient . Subject clinically significant condition , opinion Investigator make subject unsuitable study participation . Subject treat experimental device within 28 day receive investigational agent within 28 day 5 halflives , whichever longer , prior Screening . Subject concurrent malignancy history malignancy ( within past 5 year ) , except nonmetastatic basal squamous cell carcinoma skin treat successfully . Subject current history alcohol and/or drug abuse . Subject use prohibited medication stop safely period . Subject stop , start change dose restricted medication within last 30 day prior Screening . Subject involved conduct study employee Astellas group , third party associate study , study site team . Subject previously receive mirabegron . Exclusion Criteria assess placebo runin period Visit 3 ( Baseline ) : Subject fulfills exclusion criterion Visit 1 ( subject need repeat screen assessment [ PVR , cough provocation test , chemistry/hematology/urinalysis ] ) . Subject noncompliant 2week placebo runin period , define take less 80 % great 120 % study medication . Subject systolic blood pressure measurement &gt; 180 mmHg diastolic blood pressure measurement &gt; 110 3day diary baseline visit .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Urinary Incontinence</keyword>
	<keyword>Mirabegron</keyword>
	<keyword>Overactive Bladder</keyword>
</DOC>